"AstraZeneca’s AL amyloidosis drug fails to impress in Phase III" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

AstraZeneca on Wednesday said that its experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of AL amyloidosis, a rare condition that causes a buildup of ...

AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare ...

Hereditary amyloidosis is usually caused by inherited genetic mutations that cause abnormal amyloid proteins to build up and damage different organs in the body. Here’s what you need to know ...

Amyloidosis has “nonspecific” symptoms, meaning they can be the result of many medical conditions and problems, so identifying and diagnosing the disease is difficult. Here are the steps your ...

Carpal tunnel syndrome was linked to wild-type transthyretin amyloidosis in new research, highlighting the importance of ...

Amyloidosis is classified into three main forms depending on the cause of the condition. The condition is also referred to as either localized when only one site of the body is affected, or ...

Treatment options have also been limited — Lousada, now CEO of the nonprofit Amyloidosis Research Consortium in Newton, Massachusetts, was fortunate to survive thanks to a stem cell transplant that is ...

Localized amyloidosis is usually less serious than the systemic form. Diagnosis is also complicated by the fact that the symptoms of amyloidosis are similar to those seen in other conditions that ...